Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.

Publication ,  Journal Article
Zhang, T; Armstrong, AJ
Published in: Curr Oncol Rep
January 2016

Men with metastatic castration-resistant prostate cancer (mCRPC) frequently have circulating tumor cells (CTCs) that are detectable in their peripheral blood. The CellSearch® method of enumerating CTCs is presently the only FDA-cleared CTC test available clinically for men with mCRPC and has been shown to have prognostic significance in this setting, both before and during systemic therapy. Clinical utility, reflecting the ability of this test to favorably change outcomes, is a more controversial and higher bar. The CellSearch® CTC assay can provide updated prognostic and potentially surrogate information in specific clinical scenarios and in clinical trials, but formal randomized trials of clinical utility remain an unmet clinical need. Recent data suggest that CTCs may harbor genetic information (such as the androgen receptor splice variant 7, AR-V7) relevant to changing clinical management and predicting treatment sensitivity or resistance to cancer therapies such as enzalutamide, abiraterone, and taxane chemotherapies. Further molecular characterization of CTCs, cell-free DNA, or RNA can also provide additional information that may have clinical utility. Thus, CTC research is moving toward predictive medicine, based on the biologic characterization and improvements in clinical outcomes associated with heterogeneous cell types both within and between patients.

Duke Scholars

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

January 2016

Volume

18

Issue

1

Start / End Page

3

Location

United States

Related Subject Headings

  • Receptors, Androgen
  • Prostatic Neoplasms, Castration-Resistant
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplastic Cells, Circulating
  • Neoplasm Recurrence, Local
  • Male
  • Humans
  • Clinical Laboratory Techniques
  • Biomarkers, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, T., & Armstrong, A. J. (2016). Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Curr Oncol Rep, 18(1), 3. https://doi.org/10.1007/s11912-015-0490-9
Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Curr Oncol Rep 18, no. 1 (January 2016): 3. https://doi.org/10.1007/s11912-015-0490-9.
Zhang T, Armstrong AJ. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Curr Oncol Rep. 2016 Jan;18(1):3.
Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Curr Oncol Rep, vol. 18, no. 1, Jan. 2016, p. 3. Pubmed, doi:10.1007/s11912-015-0490-9.
Zhang T, Armstrong AJ. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Curr Oncol Rep. 2016 Jan;18(1):3.
Journal cover image

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

January 2016

Volume

18

Issue

1

Start / End Page

3

Location

United States

Related Subject Headings

  • Receptors, Androgen
  • Prostatic Neoplasms, Castration-Resistant
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplastic Cells, Circulating
  • Neoplasm Recurrence, Local
  • Male
  • Humans
  • Clinical Laboratory Techniques
  • Biomarkers, Tumor